scholarly journals Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients

2020 ◽  
Vol 17 (18) ◽  
pp. 3112-3124
Author(s):  
Chung-Che Wu ◽  
Titus Ime Ekanem ◽  
Nam Nhut Phan ◽  
Do Thi Thuy Loan ◽  
Sz-Ying Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Pituitary Tumor ◽  
Breast Cancer Patients ◽  
Pituitary Tumor Transforming Gene ◽  
Gene Signatures ◽  
Clinical Breast ◽  
Transforming Gene

scholarly journals Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients

2012 ◽  
Vol 28 (6) ◽  
pp. 2255-2263 ◽  
Author(s):  
ATHANASIOS ARMAKOLAS ◽  
GEORGE P. STATHOPOULOS ◽  
ADRIANOS NEZOS ◽  
APOSTOLOS THEOS ◽  
MARTHA STATHAKI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Gene Signatures ◽  
New Gene

Early breast cancer response to neoadjuvant chemotherapy: Defining the optimal timing and response rate using clinical tumor measurement.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 121-121
Author(s):  
Dominique Boudreau ◽  
Fabiano Santos ◽  
Andre Robidoux ◽  
Jean-Francois Boileau
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Breast Examination ◽  
Optimal Timing ◽  
Early Prediction ◽  
Breast Cancer Patients ◽  
Breast Examination ◽  
Clinical Breast ◽  
Her 2 ◽  
Time Point

121 Background: Breast cancer pathological complete response (pCR) following neoadjuvant therapy (NAT) is associated with better survival in some tumor subtypes. There is interest in identifying methods to increase early prediction of pCR during NAT. A simple and inexpensive technique such as early clinical breast examination has been shown to correlate with pCR during NAT in some studies. However, the optimal timing of the measurement and the best tumor response (TR) rate to predict pCR still need to be defined. Methods: We conducted a retrospective cohort study of patients prospectively enrolled in the following NSABP trials in one academic center (Montreal, Canada): B-40, B-41, FB-AX-003, FB-4, FB-5 and FB-6. Patients with T4 disease or disease progression were excluded. Clinical tumor measurements were recorded before each cycle of NAT. TR was measured as the percentage decrease in the largest tumor diameter. ROC curves for TR measurements at each time point were generated, comparing areas under the curve using the DeLong method. P-value ² 0.05 was considered significant. Results: We analyzed data of 155 patients recruited from Aug. 2005 to May 2011. Results are presented in Table 1. The best time point to predict pCR was after cycle 2. At this time point, a TR of 46% was the best cutoff value to predict for pCR. Among hormone receptor positive (HR+) and HER-2 positive (HER-2+) breast cancer patients, a TR of 47% after cycle 2 was significantly predictive for pCR. These findings were similar using a 50% TR cutoff after 2 cycles. Conclusions: Observing a 50% reduction in largest tumour diameter on clinical breast examination after cycle 2 of NAT is predictive for pCR in HR+ and HER-2+ breast cancer patients. We recommend using this definition of clinical response in future trials evaluating novel methods to improve early prediction of pCR during NAT. [Table: see text]

scholarly journals Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Jean-Sébastien Milanese ◽  
Chabane Tibiche ◽  
Jinfeng Zou ◽  
Zhigang Meng ◽  
Andre Nantel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Cell Function ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Breast Cancer Patients ◽  
Sequencing Data ◽  
Germline Variants ◽  
Gene Signatures

Abstract Germline variants such as BRCA1/2 play an important role in tumorigenesis and clinical outcomes of cancer patients. However, only a small fraction (i.e., 5–10%) of inherited variants has been associated with clinical outcomes (e.g., BRCA1/2, APC, TP53, PTEN and so on). The challenge remains in using these inherited germline variants to predict clinical outcomes of cancer patient population. In an attempt to solve this issue, we applied our recently developed algorithm, eTumorMetastasis, which constructs predictive models, on exome sequencing data to ER+ breast (n = 755) cancer patients. Gene signatures derived from the genes containing functionally germline variants significantly distinguished recurred and non-recurred patients in two ER+ breast cancer independent cohorts (n = 200 and 295, P = 1.4 × 10−3). Furthermore, we compared our results with the widely known Oncotype DX test (i.e., Oncotype DX breast cancer recurrence score) and outperformed prediction for both high- and low-risk groups. Finally, we found that recurred patients possessed a higher rate of germline variants. In addition, the inherited germline variants from these gene signatures were predominately enriched in T cell function, antigen presentation, and cytokine interactions, likely impairing the adaptive and innate immune response thus favoring a pro-tumorigenic environment. Hence, germline genomic information could be used for developing non-invasive genomic tests for predicting patients’ outcomes in breast cancer.

Case-Based Retrieval Approach of Clinical Breast Cancer Patients

2015 ◽  
Author(s):  
Heba Ayeldeen ◽  
Mohamed Abd Elfattah ◽  
Olfat Shaker ◽  
Aboul Ella Hassanien ◽  
Tai-Hoon Kim
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Clinical Breast ◽  
Case Based

scholarly journals Germline genetic variants associated with leukocyte-genes predict tumor recurrence in breast cancer patients

2018 ◽  
Author(s):  
Jean-Sébastien Milanese ◽  
Chabane Tibiche ◽  
Jinfeng Zou ◽  
Zhi Gang Meng ◽  
Andre Nantel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Genetic Variants ◽  
Cell Function ◽  
Breast Cancer Patients ◽  
Sequencing Data ◽  
Germline Variants ◽  
Gene Signatures ◽  
Cytokine Interactions

AbstractGermline genetic variants such as BRCA1/2 play an important role in tumorigenesis and clinical outcomes of cancer patients. However, only a small fraction (i.e., 5-10%) of inherited variants has been associated with clinical outcomes (e.g., BRCA1/2, APC, TP53, PTEN and so on). The challenge remains in using these inherited germline variants to predict clinical outcomes of cancer patient population. In an attempt to solve this issue, we applied our recently developed algorithm, eTumorMetastasis, which constructs predictive models, on exome sequencing data to ER+ breast (n=755) cancer patients. Gene signatures derived from the genes containing functionally germline genetic variants significantly distinguished recurred and non-recurred patients in two ER+ breast cancer independent cohorts (n=200 and 295, P=1.4×10−3). Furthermore, we found that recurred patients possessed a higher rate of germline genetic variants. In addition, the inherited germline variants from these gene signatures were predominately enriched in T cell function, antigen presentation and cytokine interactions, likely impairing the adaptive and innate immune response thus favoring a pro-tumorigenic environment. Hence, germline genomic information could be used for developing non-invasive genomic tests for predicting patients’ outcomes (or drug response) in breast cancer, other cancer types and even other complex diseases.

Clinical Significance of Pituitary Tumor Transforming Gene 1 and Transgelin-2 in Pancreatic Cancer

2013 ◽  
Vol 26 (1) ◽  
pp. 147-156 ◽  
Author(s):  
H. Lin ◽  
Q-L. Chen ◽  
X-Y. Wang ◽  
W. Han ◽  
T-Y. He ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Pituitary Tumor ◽  
Human Pancreatic Cancer ◽  
Actin Binding ◽  
Pituitary Tumor Transforming Gene ◽  
Positive Expression ◽  
Cancer Tissues ◽  
Transforming Gene

Human pituitary tumor transforming gene 1 (PTTG1) is an oncogenic transcription factor that is overexpressed in many malignancies, especially cancers with metastatic potential, while transgelin-2 (TAGLN2) is an actin-binding protein shown to be a tumor suppressor. However, the expression and clinical significance of PTTG1 and TAGLN2 in pancreatic cancer remain unclear. The present study aimed to investigate the expression and clinical significance of PTTG1 and TAGLN2 in human primary pancreatic cancer. Seventy-five cases of human pancreatic cancer tissues were collected. The expression of PTTG1 and TAGLN2 protein was assessed using immunohistochemistry (IHC) through tissue microarray procedure. The clinicopathologic characteristics of all patients were analyzed. As a result, the expression of PTTG1 and TAGLN2 in cancerous tissues showed the positive staining mainly in the cytoplasm, and they were found in cancerous tissues with higher strong reactivity rate compared with the adjacent non-cancer tissues (ANCT) (56.0% vs 22.7%, P<0.001; 100% vs 84%, P=0.002), elevating with the ascending order of tumor malignancy. Furthermore, the positive expression of PTTG1 was associated with the gender of pancreatic cancer patients, but did not correlate with their age, pathological styles, tumor size, tumor sites, TNM staging, perineural infiltration and distant metastasis (each P>0.05). In addition, Spearman rank correlation analysis showed the positive correlation of PTTG1 with TAGLN2 (r=0.624, P<0.001). Taken together, PTTG1 and TAGLN2 are highly expressed in human pancreatic cancer, and the positive expression of PTTG1 is associated with the gender of cancer patients, suggesting that it may represent a potential therapeutic target for the treatment of pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document